{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:28:48Z","timestamp":1792301328254,"version":"4.4.0"},"reference-count":41,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The availability of highly effective direct-acting antivirals (DAAs) that cure individuals infected with HCV has changed completely the natural history of HCV infection and chronic hepatitis C. In sustained responders to DAAs, the most common clinical-pathologic outcome has become liver disease regression, cirrhosis re-compensation, and the de-listing of transplant candidates. However, careful scrutiny of liver disease cofactors and outcome predictors in treated patients is mandatory for an appropriate personalized surveillance of the residual risk for hepatocellular carcinoma. Since successful treatment with DAAs does not confer protective immunity against HCV reinfection, an effective vaccine is critically needed to control HCV infection. Meanwhile, it is mandatory to enhance universal access to DAAs, to test asymptomatic high-risk groups who are the main source of transmission, and to screen people who inject drugs (PWID), men who have sex with men (MSM), and sex workers, and to assure safe medical procedures with the provision of disposable needle and syringes.<\/jats:p>","DOI":"10.3390\/v17030319","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T04:46:37Z","timestamp":1740545197000},"page":"319","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Natural History of Hepatitis C Virus Infection and Disease in the Era of Curative Therapy with Direct-Acting Antivirals"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8364-9152","authenticated-orcid":false,"given":"Maurizia Rossana","family":"Brunetto","sequence":"first","affiliation":[{"name":"Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy"},{"name":"Institute of Biostructure and Bioimaging, National Research Council, Via De Amicis 95, 80145 Naples, Italy"},{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Pisa University Hospital, Via Roma 55, 56126 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9942-0328","authenticated-orcid":false,"given":"Ferruccio","family":"Bonino","sequence":"additional","affiliation":[{"name":"Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy"},{"name":"Institute of Biostructure and Bioimaging, National Research Council, Via De Amicis 95, 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"ref_1","unstructured":"(2016). Combating Hepatitis B and C to Reach Elimination by 2030, The World Health Organization (WHO)."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2020). EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol., 73, 1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/liv.14324","article-title":"Global timing of hepatitis C virus elimination in high-income countries","volume":"40","author":"Razavi","year":"2020","journal-title":"Liver Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"333549231224199","DOI":"10.1177\/00333549231224199","article-title":"Hepatitis C Virus Testing, Infection, and Cases Reported Through Public Health Surveillance During Expanded Screening Recommendations, United States, 2013\u20132021","volume":"12","author":"Ly","year":"2024","journal-title":"Public Health Rep."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Li, Y.Q., Ghafari, M., Holbrook, A.J., Boonen, I., Amor, N., Catalano, S., Webster, J.P., Li, Y.Y., Li, H.T., and Vergote, V. (2023). The evolutionary history of hepaciviruses. bioRxiv.","DOI":"10.1101\/2023.06.30.547218"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"veab036","DOI":"10.1093\/ve\/veab036","article-title":"Molecular detection and genomic characterization of diverse hepaciviruses in African rodents","volume":"7","author":"Bletsa","year":"2021","journal-title":"Virus Evol."},{"key":"ref_8","unstructured":"King, K.C., and Strony, R. (2024). Needlestick. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jhep.2024.04.004","article-title":"B cell characteristics define HCV reinfection outcome","volume":"81","author":"Underwood","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"The Lancet Gastroenterology Hepatology (2021). The hunt for a vaccine for hepatitis C virus continues. Lancet Gastroenterol. Hepatol., 6, 253.","DOI":"10.1016\/S2468-1253(21)00073-X"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/cid\/ciz949","article-title":"Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era","volume":"71","author":"Ingiliz","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1016\/S2352-3018(20)30301-5","article-title":"ATHENA observational cohort. HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: A retrospective cohort study","volume":"8","author":"Smit","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3018(22)00077-7","article-title":"Risk of hepatitis C reinfection following successful therapy among people living with HIV: A global systematic review, meta-analysis, and meta-regression","volume":"9","author":"Hajarizadeh","year":"2022","journal-title":"Lancet HIV"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1097\/QAD.0000000000003651","article-title":"React Study Group. Reinfection incidence and risk among people treated for recent hepatitis C virus infection","volume":"37","author":"Martinello","year":"2023","journal-title":"AIDS"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2352-3018(23)00267-9","article-title":"Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010\u20132019: An analysis of data from a consortium of prospective cohort studies","volume":"11","author":"Boyd","year":"2024","journal-title":"Lancet HIV"},{"key":"ref_16","first-page":"e0082","article-title":"Immediate treatment for recent hepatitis C infection in people with high-risk behaviors: A systematic review and meta-analysis","volume":"7","author":"Macdonald","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Chu, M., Guo, Y., Yang, S., Abudurusuli, G., Frutos, R., and Chen, T. (2022). Feasibility of Hepatitis C Elimination in China: From Epidemiology, Natural History, and Intervention Perspectives. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.884598"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.gastro.2018.10.033","article-title":"What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?","volume":"156","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jhep.2021.05.028","article-title":"Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study","volume":"75","author":"Janjua","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_20","first-page":"100658","article-title":"Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: A large population-based study in British Columbia, Canada","volume":"29","author":"Jeong","year":"2023","journal-title":"Lancet Reg. Health Am."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"Veldt","year":"2012","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2169\/internalmedicine.51.8404","article-title":"Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection","volume":"51","author":"Takahashi","year":"2012","journal-title":"Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: A meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.26892","article-title":"Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents","volume":"63","author":"Sise","year":"2016","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: A prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/jvh.13507","article-title":"Natural history of hepatitis C virus infection in a large national seroconversion cohort in the direct-acting antiviral agent era: Results from ERCHIVES","volume":"28","author":"Butt","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jceh.2022.08.002","article-title":"Recompensation in Cirrhosis: Current Evidence and Future Directions","volume":"13","author":"Sharma","year":"2023","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.dld.2022.12.014","article-title":"The Baveno VII concept of cirrhosis recompensation","volume":"55","author":"Reiberger","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jhep.2022.01.029","article-title":"Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions","volume":"77","author":"Leslie","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1002\/hep.31500","article-title":"Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients with Cirrhotic HCV Treated with DAAs","volume":"72","author":"Degasperi","year":"2020","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.31588","article-title":"A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV advanced fibrosis","volume":"72","author":"Manzano","year":"2020","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zou, Y., Yue, M., Jia, L., Wang, Y., Chen, H., Zhang, A., Xia, X., Liu, W., Yu, R., and Yang, S. (2023). Accurate prediction of HCC risk after SVR in patients with hepatitis C cirrhosis based on longitudinal data. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11628-1"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.cgh.2022.04.013","article-title":"Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure with Direct-acting Antivirals: A Systematic Review and Meta-analysis","volume":"21","author":"Kim","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1097\/MPG.0000000000003481","article-title":"Epidemiology and Natural History of Childhood-Acquired Chronic Hepatitis C: A Single-Center Long-Term Prospective Study","volume":"75","author":"Stinco","year":"2022","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/jvh.13795","article-title":"Risk factors for liver-related and non-liver-related mortality following a sustained virological response after direct-acting antiviral treatment for hepatitis C virus infection in a real-world cohort","volume":"30","author":"Kozuka","year":"2023","journal-title":"J. Viral Hepat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jhep.2022.09.019","article-title":"Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan","volume":"78","author":"Tsai","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/liv.15528","article-title":"Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK","volume":"43","author":"Hamill","year":"2023","journal-title":"Liver Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/MEG.0000000000002479","article-title":"Fib-4 index predicts prognosis after achievement of sustained virologic response following direct-acting antiviral treatment in patients with hepatitis C virus infection","volume":"35","author":"Ideno","year":"2023","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"(2021). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update. J. Hepatol., 75, 659\u2013689.","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.4254\/wjh.v13.i11.1663","article-title":"Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals","volume":"13","author":"Cerrito","year":"2021","journal-title":"World J. Hepatol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/3\/319\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:42:37Z","timestamp":1760028157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/3\/319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["v17030319"],"URL":"https:\/\/doi.org\/10.3390\/v17030319","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]}}}